Hill MP - Search Results

1

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.

Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ. Hill MP, et al. Mov Disord. 2006 Dec;21(12):2090-5. doi: 10.1002/mds.21106. Mov Disord. 2006. PMID: 16991143

2

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.

Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Hill MP, et al. Mov Disord. 2003 Nov;18(11):1301-5. doi: 10.1002/mds.10542. Mov Disord. 2003. PMID: 14639671

3

Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.

Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Hill MP, et al. J Pharmacol Exp Ther. 2004 Jul;310(1):386-94. doi: 10.1124/jpet.104.066191. Epub 2004 Mar 5. J Pharmacol Exp Ther. 2004. PMID: 15004218

4

Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets.

Hill MP, Brotchie JM, Crossman AR, Bezard E, Michel A, Grimée R, Klitgaard H. Hill MP, et al. Clin Neuropharmacol. 2004 Jul-Aug;27(4):171-7. doi: 10.1097/01.wnf.0000135478.70905.3d. Clin Neuropharmacol. 2004. PMID: 15319703

5

Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.

Kobylecki C, Hill MP, Crossman AR, Ravenscroft P. Kobylecki C, et al. Among authors: hill mp. Mov Disord. 2011 Nov;26(13):2354-63. doi: 10.1002/mds.23867. Epub 2011 Sep 23. Mov Disord. 2011. PMID: 21953539

6

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Fox SH, et al. Mov Disord. 2002 Nov;17(6):1180-7. doi: 10.1002/mds.10289. Mov Disord. 2002. PMID: 12465055

7

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. Savola JM, et al. Mov Disord. 2003 Aug;18(8):872-83. doi: 10.1002/mds.10464. Mov Disord. 2003. PMID: 12889076

8

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.

Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M. Millan MJ, et al. J Pharmacol Exp Ther. 2004 Jun;309(3):921-35. doi: 10.1124/jpet.103.062414. Epub 2004 Feb 20. J Pharmacol Exp Ther. 2004. PMID: 14978195

9

Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.

Hughes NR, McKnight AT, Woodruff GN, Hill MP, Crossman AR, Brotchie JM. Hughes NR, et al. Among authors: hill mp. Mov Disord. 1998 Mar;13(2):228-33. doi: 10.1002/mds.870130206. Mov Disord. 1998. PMID: 9539334

10

Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.

Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Nash JE, et al. Among authors: hill mp. Exp Neurol. 2000 Sep;165(1):136-42. doi: 10.1006/exnr.2000.7444. Exp Neurol. 2000. PMID: 10964492

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124 results

Search Page

Filters